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In a previous issue of Arthritis Research & Th erapy, 
Nancy Olsen and colleagues from the Penn State Hershey 
Medical Center and the University of Texas Southwestern 
Medical Center present an analysis of a wide range of 
autoantibodies in patients with ‘incomplete’ SLE [1]. 
Within the Dallas Regional Autoimmune Disease registry 
(DRADR) cohort, they have followed patients who, with 
one exception, did not fulﬁ ll American College of 
Rheumatology criteria for systemic lupus erythematosus 
(SLE) at baseline using an autoantigen array.
Out of 22 patients, only 3 developed additional SLE 
criteria during a follow-up of 3.8 ± 0.6 years. Th ese three 
patients showed some possible diﬀ erences in their serology. 
At baseline, they had higher titers of antibodies to hemo-
cyanin and PL-7 (threonyl-tRNA synthetase), and some-
what higher levels of antibodies to thyroglobulin, thyroid 
peroxidase, proliferating cell nuclear antigen, β2-micro-
globulin, and C1q, not all of which are typically associated 
with SLE. On follow-up, these patients showed a 
signiﬁ  cant increase in anti-La/SS-B and LC1 (liver 
cytosol type 1) antibodies, and a trend towards increasing 
anti-Ro/SS-A antibodies. In addition, they were more 
likely to develop new antibody speciﬁ cities, in contrast to 
the remaining patients, where this was seen in less than 
one-third.
Th e authors mainly present their work as an attempt to 
ﬁ nding predictors for developing SLE. While the approach 
is of interest, the sample size, the limited follow-up time, 
and some technical issues preclude ﬁ rm conclusions as of 
yet. Only three patients progressed to SLE - the others 
maintained a stable phenotype. Th is may indicate that 
the majority of patients had already reached a stable 
phenotype of ‘undiﬀ erentiated connective tissue disease’ 
at enrollment in the study. However, the few patients who 
progressed clinically may hint at early immune events 
that deﬁ ne SLE.
In a variety of autoimmune diseases, speciﬁ c autoanti-
bodies clearly precede disease. In autoimmune blistering 
diseases of the skin, there is evidence that antibodies 
determine both clinical phenotype and disease onset. 
Desmoglein-1 antibodies are associated with pemphigus 
foliaceus, while desmoglein-3 antibodies occur in pem-
phigus vulgaris. Blistering occurs at the sites where the 
targets of these antibodies occur naturally [2]. Intra-
molecular epitope spreading, to particular epitopes of 
desmo glein-1, apparently explains the onset of clinical 
features of disease, which reverses in disease remission 
[3].
In rheumatoid arthritis, antibodies to citrullinated 
peptides, which are quite speciﬁ c for the disease, may be 
present for years in individuals with no joint symptoms 
[4]. In contrast to pemphigus, however, no individual 
epitope of anti-citrullinated protein antibodies has been 
associated with the onset of clinical disease. Rather, the 
range of speciﬁ cities, and the titres of antibodies, increase 
as patients approach disease onset [5].
In SLE, likewise, as has been known for some time, 
autoantibodies are present for years before the diagnosis 
[6], and anti-double-stranded DNA, anti-Ro, anti-La, and 
anti-phospholipid antibodies, in particular. Th ese anti-
bodies also predict development of SLE in patients with 
undiﬀ erentiated connective tissue disease and patients 
fulﬁ lling criteria of mixed connective tissue disease [7]. 
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However, the potential spectrum of antibodies in SLE is 
much broader than in the above-mentioned diseases [8].
Th ese authors now demonstrate in an unbiased longi-
tudinal analysis that these less typical SLE autoantibodies 
may have prognostic signiﬁ cance. Antibodies to 
hemocyanin, PL-7, thyroglobulin, thyroid peroxidase, or 
proliferating cell nuclear antigen are not among those 
usually provoking a search for an underlying diagnosis of 
SLE. Indeed, some of them are associated with other 
autoimmune diseases, such as anti-thyroid peroxidase 
and anti-thyroglobulin with autoimmune thyroid disease, 
or anti-PL-7 with polymyositis (Figure 1). In their work, 
the number of antigens targeted by autoantibodies 
appears more important than any given speciﬁ city, and a 
rapid increase in the number of antigens targeted by 
autoantibodies accompanied transformation into SLE.
Th e ﬁ ndings in the manuscript by Olsen and colleagues 
thus paint a picture of increasing B cell autoreactivity, 
manifest as multiple autoantibodies during the progres-
sion of clinical SLE. Th ere is undoubtedly a propensity to 
developing antibodies to speciﬁ c nuclear antigens in SLE. 
Mechanistically this has been linked to defects in DNA 
processing, apoptotic clearance and Toll-like receptor 
sensing of nucleic antigens [9]. Most of the patients in 
this series were ANA positive at inclusion. However, 
broadening of the antibody spectrum, with much less 
speciﬁ city, may constitute a second step toward SLE. On 
a cellular level, the same concept is reﬂ ected by a marked 
increase in plasmablasts in active SLE, of which only a 
subset make anti-double-stranded DNA antibodies [10].
A range of known mechanisms may underlie this 
broader reactivity. Among others, polymorphisms in 
BLK, PTPN22 and Src family kinases have associations 
with SLE, and may lead to generalized B- and T-cell 
hyper-responsiveness [11]. Interferon-α production has 
been strongly associated with SLE. Excess production by 
plasmacytoid dendritic cells of type 1 interferons may, in 
response to Toll-like receptor stimulation by nuclear 
anti gens and immune complexes, provoke a more 
general ized activation of humoral immunity. In other 
words, B cells may be intrinsically hyper-responsive and 
auto reactive, or they may simply be responding appro-
priately to inappropriate signals from a defective innate 
immune system (or both).
Similarly, the reasons why the majority of patients did 
not progress, despite autoantibodies at baseline, are also 
unclear, but may be of importance to understanding 
patho genesis. For example, preservation of certain 
normal tolerance mechanisms in these patients may have 
been suﬃ  cient to keep B-cell autoreactivity in check. One 
might conclude, therefore, that autoantibodies are neces-
sary, but not suﬃ  cient, to cause clinical SLE.
Th e results of this unique cohort therefore indicate that 
no one antibody target or class of autoantibody mark the 
transition to SLE, but rather a generalized broadening of 
the antibody repertoire. Recognizing this may be relevant 
to both better understand SLE diagnosis and classiﬁ -
cation and help target studies on abnormalities under-
lying lupus.
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